Oscar Health, Inc. (NYSE:OSCR) Receives $20.78 Consensus Target Price from Brokerages

Shares of Oscar Health, Inc. (NYSE:OSCR) have earned an average recommendation of “Hold” from the twelve analysts that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, seven have assigned a hold recommendation, three have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month target price among brokers that have covered the stock in the last year is $20.7778.

OSCR has been the topic of several research reports. Jefferies Financial Group upgraded Oscar Health from an “underperform” rating to a “hold” rating and lifted their price target for the company from $10.00 to $16.00 in a research report on Monday, April 20th. Wall Street Zen raised Oscar Health from a “buy” rating to a “strong-buy” rating in a research report on Sunday, June 14th. Wells Fargo & Company set a $20.00 price objective on Oscar Health and gave the company an “equal weight” rating in a research report on Thursday, June 4th. Robert W. Baird upped their target price on shares of Oscar Health from $15.00 to $19.00 and gave the stock a “neutral” rating in a research report on Thursday, May 7th. Finally, Wolfe Research began coverage on shares of Oscar Health in a research report on Tuesday, May 5th. They issued a “peer perform” rating on the stock.

Insider Buying and Selling at Oscar Health

In other Oscar Health news, insider Adam Mcananey sold 9,859 shares of the firm’s stock in a transaction that occurred on Tuesday, June 2nd. The shares were sold at an average price of $21.94, for a total transaction of $216,306.46. Following the completion of the transaction, the insider owned 218,096 shares of the company’s stock, valued at approximately $4,785,026.24. This trade represents a 4.32% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Mark T. Bertolini sold 624,244 shares of Oscar Health stock in a transaction that occurred on Tuesday, June 30th. The shares were sold at an average price of $28.48, for a total transaction of $17,778,469.12. Following the transaction, the chief executive officer owned 7,751,570 shares of the company’s stock, valued at $220,764,713.60. The trade was a 7.45% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 3,662,466 shares of company stock valued at $105,145,815 over the last three months. 22.64% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Oscar Health

Institutional investors have recently modified their holdings of the stock. Thrive Capital Management LLC raised its position in shares of Oscar Health by 33.4% in the 4th quarter. Thrive Capital Management LLC now owns 6,343,617 shares of the company’s stock worth $85,258,000 after purchasing an additional 1,588,395 shares during the last quarter. Baird Financial Group Inc. bought a new stake in Oscar Health during the 1st quarter valued at about $159,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Oscar Health by 4.3% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 215,650 shares of the company’s stock valued at $2,827,000 after purchasing an additional 8,879 shares in the last quarter. Jones Financial Companies Lllp increased its stake in Oscar Health by 7,473.3% during the 1st quarter. Jones Financial Companies Lllp now owns 2,272 shares of the company’s stock valued at $30,000 after purchasing an additional 2,242 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in Oscar Health by 39.0% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 470,590 shares of the company’s stock worth $6,169,000 after buying an additional 132,149 shares during the last quarter. 75.70% of the stock is owned by hedge funds and other institutional investors.

Oscar Health Price Performance

OSCR stock opened at $29.59 on Thursday. The company has a debt-to-equity ratio of 0.26, a current ratio of 1.11 and a quick ratio of 1.11. Oscar Health has a 1 year low of $10.69 and a 1 year high of $33.10. The firm has a 50-day moving average of $27.07 and a 200 day moving average of $19.09. The company has a market cap of $8.92 billion, a P/E ratio of -50.14, a PEG ratio of 1.63 and a beta of 2.34.

Oscar Health (NYSE:OSCR) last posted its quarterly earnings data on Wednesday, May 6th. The company reported $2.07 earnings per share for the quarter, beating the consensus estimate of $1.11 by $0.96. Oscar Health had a negative return on equity of 3.26% and a negative net margin of 0.30%.The business had revenue of $4.65 billion for the quarter, compared to analysts’ expectations of $4.90 billion. During the same period in the previous year, the firm posted $0.92 EPS. The business’s revenue was up 52.6% on a year-over-year basis. On average, sell-side analysts forecast that Oscar Health will post 0.59 EPS for the current year.

Oscar Health Company Profile

Oscar Health, trading on the New York Stock Exchange under the ticker OSCR, is a technology-driven health insurance company headquartered in New York, New York. Founded in 2012 by Mario Schlosser, Joshua Kushner and Kevin Nazemi, the company was built with the goal of simplifying healthcare coverage and enhancing member experience. Oscar leverages a proprietary digital platform to streamline plan enrollment, claims administration and member support, distinguishing itself in the individual, family and small group insurance markets.

The company’s primary products include on-exchange individual and family medical plans under the Affordable Care Act, off-exchange plans, as well as Medicare Advantage offerings.